# Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

> **NCT05818085** · PHASE2,PHASE3 · COMPLETED · sponsor: **Atom Therapeutics Co., Ltd** · enrollment: 300 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** ABP-671
- **DRUG:** Allopurinol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05818085
- **Lead sponsor:** Atom Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-11
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-03-30
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05818085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05818085, "Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05818085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*